NEJM / EAS 2026 – Heart-2 Trial
NEJM / EAS 2026 – Heart-2 Trial
VERVE-102, a one-time IV therapy designed to permanently inactivate the PCSK9 gene, reduced LDLby up to 62%, with sustained benefit through 1 year of follow-up.
By preserving LDL receptors in the liver, it enhances clearance of LDL cholesterol from the bloodstream.
Source: NEJM, Heart-2 Phase I Trial, EAS 2026.
TCTMD Coverage
https://www.tctmd.com/news/
